CD47 and neoplasm: This first-in-class compound is a cyclic pentapeptide that has been demonstrated to reprogram myeloid-derived suppressor cells (MDSCs) to produce TSP-1 in the TME, which can then bind to CD36 and CD47 on tumor and endothelial cells [92,93].